MUSTANG BIO, INC. (MBIO) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does MUSTANG BIO, INC. Do?
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. MUSTANG BIO, INC. (MBIO) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Manuel Litchman and employs approximately 100 people. With a market capitalization of $6M, MBIO is one of the notable companies in the Healthcare sector.
MUSTANG BIO, INC. (MBIO) Stock Rating — Avoid (April 2026)
As of April 2026, MUSTANG BIO, INC. receives a Avoid rating with a composite score of 21.7/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.MBIO ranks #4,221 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, MUSTANG BIO, INC. ranks #754 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
MBIO Stock Price and 52-Week Range
MUSTANG BIO, INC. (MBIO) currently trades at $0.70. The stock lost $0.04 (5.8%) in the most recent trading session. The 52-week high for MBIO is $7.00, which means the stock is currently trading -90.0% from its annual peak. The 52-week low is $0.53, putting the stock 31.9% above its annual trough. Recent trading volume was 53K shares, suggesting relatively thin trading activity.
Is MBIO Overvalued or Undervalued? — Valuation Analysis
MUSTANG BIO, INC. (MBIO) carries a value factor score of 15/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.59x, versus the sector average of 2.75x.
At current multiples, MUSTANG BIO, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
MUSTANG BIO, INC. Profitability — ROE, Margins, and Quality Score
MUSTANG BIO, INC. (MBIO) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -29.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -15.9% versus the sector average of -33.1%.
Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
MBIO Debt, Balance Sheet, and Financial Health
MUSTANG BIO, INC. has a debt-to-equity ratio of 85.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.22x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $19M.
MBIO has a beta of 0.76, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for MUSTANG BIO, INC. is 27/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
MUSTANG BIO, INC. Revenue and Earnings History — Quarterly Trend
In TTM 2026, MUSTANG BIO, INC. reported revenue of $0 and earnings per share (EPS) of $-0.39. Net income for the quarter was $-3M. Operating income came in at $-3M.
In FY 2025, MUSTANG BIO, INC. reported revenue of $0 and earnings per share (EPS) of $-0.39. Net income for the quarter was $-2M. Operating income came in at $-2M.
In Q3 2025, MUSTANG BIO, INC. reported revenue of $0 and earnings per share (EPS) of $-0.07. Net income for the quarter was $-468,000. Operating income came in at $-624,000.
In Q2 2025, MUSTANG BIO, INC. reported revenue of $0 and earnings per share (EPS) of $-0.19. Net income for the quarter was $-762,000. Operating income came in at $-885,000.
Over the past 8 quarters, MUSTANG BIO, INC. has experienced revenue contraction from $0 to $0. Investors analyzing MBIO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
MBIO Dividend Yield and Income Analysis
MUSTANG BIO, INC. (MBIO) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
MBIO Momentum and Technical Analysis Profile
MUSTANG BIO, INC. (MBIO) has a momentum factor score of 19/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 64/100 reflects moderate short selling activity.
MBIO vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, MUSTANG BIO, INC. (MBIO) ranks #754 out of 838 stocks based on the Blank Capital composite score. This places MBIO in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing MBIO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MBIO vs S&P 500 (SPY) comparison to assess how MUSTANG BIO, INC. stacks up against the broader market across all factor dimensions.
MBIO Next Earnings Date
No upcoming earnings date has been announced for MUSTANG BIO, INC. (MBIO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy MBIO? — Investment Thesis Summary
The quantitative profile for MUSTANG BIO, INC. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 15/100 indicates premium valuation. Momentum is weak at 19/100, a headwind for near-term performance. High volatility (stability score 27/100) increases portfolio risk.
In summary, MUSTANG BIO, INC. (MBIO) earns a Avoid rating with a composite score of 21.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MBIO stock.
Related Resources for MBIO Investors
Explore more research and tools: MBIO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MBIO head-to-head with peers: MBIO vs AZN, MBIO vs SLGL, MBIO vs VMD.